SCHEMBL24769738

SCHEMBL24769738

c1cncc(Cc2cncnc2)c1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
HRH4 Q9H3N8 1/20 0.53
HRH3 Q9Y5N1 1/20 0.53
CYP11B1 P15538 2/20 0.53
CYP11B2 P19099 2/20 0.53
CYP2A6 P11509 2/20 0.52
CHRNA7 P36544 1/20 0.52
TBXAS1 P24557 4/20 0.51
CHRNB2 P17787 2/20 0.50
CHRNA4 P43681 2/20 0.50
MMP2 P08253 1/20 0.50
NAPRT Q6XQN6 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL727185 0.91 CYP1A2 (0.62) CYP1A2CYP2D6HRH4HRH3CYP11B1
SCHEMBL29995759 0.84 CYP11B1 (0.65) CYP1A2CYP2D6HRH4HRH3CYP11B1
SCHEMBL14257669 0.84 CYP1A2 (0.56) CYP1A2CYP2D6HRH4HRH3CYP11B1
SCHEMBL177863 0.84 CYP11B1 (0.65) CYP1A2CYP2D6HRH4HRH3CYP11B1
Ammonia Solution, Strong SCHEMBL5999508 0.82 CYP11B1 (0.62) CYP1A2CYP2D6HRH4HRH3CYP11B1
Hydrochloric Acid SCHEMBL10665044 0.82 TBXAS1 (0.64) CYP1A2CYP2D6HRH4HRH3CYP11B1
SCHEMBL609110 0.81 CALM1 (0.60) HRH3CYP11B1CYP11B2TBXAS1
SCHEMBL12009180 0.80 CYP11B1 (0.48) CYP11B1CYP11B2CYP2A6
SCHEMBL25181727 0.79 CYP11B1 (0.56) CYP1A2CYP2D6HRH4HRH3CYP11B1
SCHEMBL18459207 0.79 CYP11B1 (0.56) CYP1A2CYP2D6HRH4HRH3CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders Smilebiotek Zhuhai Limited (CN) 2024-06-25 US disclosed
WO-2022263800-A1 PROCESS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2022-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders MB, MYOC, PDE6A CYP1A2 4430/4885CYP2D6 4661/4885HRH4 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.